Collplant Historical Income Statement
| CLGN Stock | USD 4.25 0.00 0.00% |
Historical analysis of Collplant Biotechnologies income statement accounts such as Interest Expense of 9.5 K, Selling General Administrative of 3.8 M or Selling And Marketing Expenses of 38.7 K can show how well Collplant Biotechnologies performed in making a profits. Evaluating Collplant Biotechnologies income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Collplant Biotechnologies's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Collplant Biotechnologies latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Collplant Biotechnologies is a good buy for the upcoming year.
Collplant |
About Collplant Income Statement Analysis
Collplant Biotechnologies Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Collplant Biotechnologies shareholders. The income statement also shows Collplant investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Collplant Biotechnologies Income Statement Chart
Add Fundamental
Cost Of Revenue
Cost of Revenue is found on Collplant Biotechnologies income statement and represents the costs associated with goods and services Collplant Biotechnologies provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most accounts from Collplant Biotechnologies' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Collplant Biotechnologies current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collplant Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Collplant Stock, please use our How to Invest in Collplant Biotechnologies guide.At this time, Collplant Biotechnologies' Total Other Income Expense Net is very stable compared to the past year. As of the 28th of November 2024, Total Revenue is likely to grow to about 11.5 M, while Depreciation And Amortization is likely to drop about 874.1 K.
| 2021 | 2023 | 2024 (projected) | Interest Expense | 37K | 10K | 9.5K | Depreciation And Amortization | 773K | 1.1M | 874.1K |
Collplant Biotechnologies income statement Correlations
Click cells to compare fundamentals
Collplant Biotechnologies Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Collplant Biotechnologies income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 4.0M | 660K | 773K | 1.1M | 1.1M | 874.1K | |
| Interest Expense | 15.1K | 63K | 34K | 37K | 10K | 9.5K | |
| Selling General Administrative | 3.6M | 4.6M | 5.9M | 6.7M | 6.6M | 3.8M | |
| Other Operating Expenses | 9.9M | 11.7M | 15.6M | 17.4M | 18.5M | 10.4M | |
| Operating Income | (7.6M) | (5.6M) | 65K | (17.1M) | (7.5M) | (7.9M) | |
| Ebit | (7.6M) | (5.6M) | 65K | (17.1M) | (7.5M) | (7.9M) | |
| Research Development | 4.4M | 4.1M | 7.6M | 10.3M | 10.5M | 5.8M | |
| Ebitda | (3.6M) | (4.9M) | 838K | (16.0M) | (6.4M) | (6.7M) | |
| Total Operating Expenses | 8.1M | 8.7M | 13.6M | 17.0M | 16.5M | 9.5M | |
| Income Before Tax | (11.2M) | (5.8M) | 237K | (16.9M) | (7.0M) | (7.4M) | |
| Total Other Income Expense Net | 378.4K | (3.5M) | (175K) | 172K | 493K | 517.7K | |
| Net Income | (14.7M) | (5.8M) | 409K | (16.8M) | (7.0M) | (7.4M) | |
| Income Tax Expense | 3.0M | 3.5M | 34K | (172K) | (1.0) | (0.95) | |
| Total Revenue | 2.3M | 6.1M | 15.6M | 299K | 11.0M | 11.5M | |
| Gross Profit | 439K | 3.1M | 13.6M | (101K) | 9.0M | 9.4M | |
| Net Income From Continuing Ops | (11.2M) | (5.8M) | 237K | (16.9M) | (6.7M) | (7.1M) | |
| Cost Of Revenue | 1.9M | 3.0M | 2.0M | 400K | 2.0M | 1.1M | |
| Net Income Applicable To Common Shares | (11.2M) | (5.8M) | 237K | (16.9M) | (19.5M) | (20.4M) | |
| Net Interest Income | (73K) | 6K | 182K | 172K | 504K | 529.2K | |
| Reconciled Depreciation | 539K | 660K | 773K | 1.1M | 1.1M | 762.6K |
Pair Trading with Collplant Biotechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Collplant Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Collplant Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Moving together with Collplant Stock
| 0.82 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.81 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Collplant Stock
| 0.8 | PHVS | Pharvaris BV | PairCorr |
| 0.69 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.63 | PMVP | Pmv Pharmaceuticals | PairCorr |
| 0.61 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.61 | PLRX | Pliant Therapeutics | PairCorr |
The ability to find closely correlated positions to Collplant Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Collplant Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Collplant Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Collplant Biotechnologies to buy it.
The correlation of Collplant Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Collplant Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Collplant Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Collplant Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collplant Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Collplant Stock, please use our How to Invest in Collplant Biotechnologies guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collplant Biotechnologies. If investors know Collplant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collplant Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.53) | Revenue Per Share 0.06 | Quarterly Revenue Growth (0.98) | Return On Assets (0.34) | Return On Equity (0.62) |
The market value of Collplant Biotechnologies is measured differently than its book value, which is the value of Collplant that is recorded on the company's balance sheet. Investors also form their own opinion of Collplant Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Collplant Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collplant Biotechnologies' market value can be influenced by many factors that don't directly affect Collplant Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collplant Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Collplant Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collplant Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.